Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 19:11:20451253211011021.
doi: 10.1177/20451253211011021. eCollection 2021.

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression

Adam Włodarczyk  1 , Wiesław J Cubała  2 , Maria Gałuszko-Węgielnik  2 , Joanna Szarmach  2
Affiliations

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression

Adam Włodarczyk et al. Ther Adv Psychopharmacol. .

Abstract

Background: There is evidence supporting the use of ketamine in treatment-resistant depression (TRD). However, there are some safety and tolerability concerns associated with ketamine. This study aimed to investigate ketamine's safety and tolerability to the central nervous system and to assess the relationship between dissociative symptomology and psychometric outcomes during and after intravenous ketamine treatment concurrent with treatment by varying psychotropic medications in treatment-refractory inpatients with major depressive disorder (MDD) and bipolar disorder (BP).

Methods: A total of 49 patients with MDD and BP were included in this study. The subjects were administered ketamine and were assessed for changes using an observational protocol.

Results: No antidepressants were associated with psychomimetic symptomatology except for citalopram (p = 0.019). Patients treated with citalopram showed a higher intensity of psychomimetic symptomatology. The use of classic mood-stabilizers was significantly associated with an increase in psychomimetic symptomatology according to the Brief Psychiatric Rating Scale (BPRS; lamotrigine p = 0.009, valproate p = 0.048, lithium p = 0.012). No sequelae were observed.

Conclusions: Despite the limitations that this study may be underpowered due to the small sample size, the sample consisted of a heterogeneous TRD population in a single site, and there no blinding of who underwent only acute ketamine administration, our observations indicate ketamine use requires close safety and tolerability monitoring with regards to psychomimetic and dissociative symptoms in TRD-BP and careful management for MDD patients.ClinicalTrials.gov identifier: NCT04226963.

Keywords: dissociation; ketamine; psychosis; safety; tolerability; treatment-resistant depression.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: W has received research support from Actavis, Eli Lilly, Minerva Neurosciences, Sunovion Pharmaceuticals, KCR, Janssen, Otsuka, Apodemus, Cortexyme, Acadia. WJC has received research support from Actavis, Alkermes, Allergan, Auspex, Biogen, Bristol-Myers Squibb, Cephalon, Eli Lilly, Ferrier, Forest Laboratories, Gedeon Richter, GW Pharmaceuticals, Janssen, KCR, Lundbeck, Orion, Otsuka, Sanofi, and Servier; he has served on speakers bureaus for Adamed, Angelini, AstraZeneca, Bristol-Myers Squibb, Celon, GlaxoSmithKline, Janssen, Krka, Lekam, Lundbeck, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, and Zentiva; and he has served as a consultant for GW Pharmaceuticals, Janssen, KCR, Quintiles, and Roche. MG-W has received research support from Janssen, Servier, Alkermes, KCR, Lilly, Biogen, Celon; JS has received research support from Actavis, Eli Lilly, Minerva Neurosciences, Sunovion Pharmaceuticals, KCR, Janssen, Otsuka, Apodemus, Cortexyme, Acadia.

Figures

Figure 1.
Figure 1.
Means and standard errors for the BPRS scores were measured after subsequent ketamine infusions in groups with and without lamotrigine coexisting treatment. *Significantly higher BPRS scores were observed between patients who were being treated with lamotrigine (n = 7) and those who were not (n = 42), with regards to BPRS score after the eighth infusion. A detailed analysis of the results showed that the BPRS score was higher after the fifth infusion compared with that after the seventh infusion. The differences between the remaining measurements were not significant (p > 0.05). BPRS, Brief Psychiatric Rating Scale.
Figure 2.
Figure 2.
Means and standard errors for the BPRS scores were measured after subsequent ketamine infusions in groups with and without citalopram coexisting treatment. *Significantly higher scores in BPRS were observed, after the second infusion between patients who were taking citalopram (n = 4) and those who were not (n = 45). BPRS, Brief Psychiatric Rating Scale.
Figure 3.
Figure 3.
Means and standard errors for the BPRS scores were measured after subsequent ketamine infusions in groups with and without coexisting lithium treatment. *Significantly higher BPRS scores were observed between patients being treated with lithium (n = 5) and those who were not (n = 44), after the sixth infusion, and after the eighth infusion. BPRS, Brief Psychiatric Rating Scale.
Figure 4.
Figure 4.
Means and standard errors for the BPRS scores were measured after subsequent ketamine infusions in groups with and without valproate coexisting treatment. *Significantly higher BPRS scores were observed between patients being treated with valproate (n = 9) and those who were not (n = 40) following the sixth infusion, and after the eighth infusion. BPRS, Brief Psychiatric Rating Scale.
See this image and copyright information in PMC

References

    1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–354. - PubMed
    1. Correia-Melo FS, Argolo FC, Araújo-de-Freitas L, et al. Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr Dis Treat 2017; 13: 1627–1632. - PMC - PubMed
    1. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment- resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793–802. - PMC - PubMed
    1. McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev 2015; 9: CD011611. - PubMed
    1. Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018; 5: 65–78. - PubMed

Associated data

LinkOut - more resources